Source: MedGen UID: 299170
A recombinant, humanized IgG1 monoclonal
antibody directed against the
interleukin-6 receptor (IL-6R) with
immunosuppressant activity. Tocilizumab
targets and binds to both the soluble form of
IL-6R (sIL-6R) and the membrane-bound form
(mIL-6R), thereby blocking the binding of IL-6
to its receptor. This prevents IL-6-mediated
signaling. Il-6, a pro-inflammatory cytokine that
plays an important role in the regulation of the
immune response, is overproduced in
autoimmune disorders and certain types of
— rheumatoid arthritis
disease-modifying antirheumatic drugs
cytokine release syndrome
juvenile idiopathic arthritis
giant cell arteritis
PRJNA134351 Combination of peripheral blood
gene expression profiles and clinical
parameters predicts response for tocilizumab
(anti-IL6) treatment in rheumatoid arthritis
PRJNA196517 Effects of tocilizumab versus
methotrexate therapy on gene expression
profiles in the early rheumatoid arthrtis
PRJNA113057 Gene Expression Analysis in
Peripheral Blood of Patients with Rheumatoid
PRJNA196596 Genome-wide analysis of EGFR
inhibitor erlotinib treatment in Head and neck,
squamous cell carcinoma's FADU, SQ20B and
PRJNA152397 Human peripheral blood cells
(PB): Effect of Tocilizumab/MRA compared to
methotrexate(MTX) treatments on rheumatoid
PRJNA312528 Identification of baseline gene
expression signatures predicting therapeutic
responses to three biologic agents in
rheumatoid arthritis: a retrospective
PRJNA307567 Mitochondrial and oxidative
stress genes are differentially expressed in
neutrophils of sJIA patients treated with
tocilizumab: a pilot microarray study
PRJNA416370 Skin gene expression is
prognostic for the trajectory of skin disease in
patients with diffuse cutaneous systemic
PRJNA360442 Whole blood gene expression
of rheumatoid arthritis
32341791 Thoughts on COVID-19 and
32320677 Complex Immune Dysregulation in
COVID-19 Patients with Severe Respiratory Failure.
32309629 Efficacy and Safety of Tocilizumab
in the Treatment of Acute Active Antibody-mediated
Rejection in Kidney Transplant Recipients.
32305359 American Society for Transplantation
and Cellular Therapy Pharmacy Special Interest
Group Position Statement on Pharmacy Practice
Management and Clinical Management for
COVID-19 in Hematopoietic Cell Transplantation
and Cellular Therapy Patients in the United
32303241 The French paediatric cohort of
Castleman disease: a retrospective report of
32293545 Treatment modalities and drug
survival in a systemic sclerosis real-life patient
32280950 Tocilizumab in patients with anti-TNF
refractory juvenile idiopathic arthritis-associated
uveitis (APTITUDE): a multicentre, single-arm,
phase 2 trial.
32274443 Concomitant herpes simplex keratitis
and autoimmune-associated ulcerative keratitis
in rheumatoid arthritis patients.
32271899 Grading and management of
cytokine release syndrome in patients treated
with tisagenlecleucel in the JULIET trial.
32267094 Comparative Risk of Diabetes Mellitus
in Patients With Rheumatoid Arthritis Treated
With Biologic or Targeted Synthetic
Disease-Modifying Drugs: A Cohort Study.
32253068 Recommendations for
coronavirus infection in rheumatic diseases
treated with biologic therapy.
32249274 Thrombocytopenia, Anasarca,
Fever, Reticulin Fibrosis/Renal Failure, and
Organomegaly (TAFRO) Syndrome with Bilateral
Adrenal Hemorrhage in Two Caucasian Patients.
32248829 Effectiveness of TOcilizumab in
comparison to Prednisone In Rheumatoid Arthritis
patients with insufficient response to
disease-modifying antirheumatic drugs (TOPIRA):
study protocol for a pragmatic trial.
32247050 Insight into 2019 novel coronavirus
- an updated intrim review and lessons from
SARS-CoV and MERS-CoV.
32234467 The cytokine release syndrome
(CRS) of severe COVID-19 and Interleukin-6 receptor
(IL-6R) antagonist Tocilizumab may be the key
to reduce the mortality.
32222713 A Case of Novel Coronavirus Disease
19 in a Chronic Hemodialysis Patient Presenting
with Gastroenteritis and Developing Severe
32210531 Giant Cell Arteritis: The Experience
of Two Collaborative Referral Centers and an
Overview of Disease Pathogenesis and
32201660 Organizing Pneumonia Induced by
Tocilizumab in a Patient with
32188441 Severe sepsis caused by serious
gastrointestinal infection in sJIA patients treated
with IL-6 receptor antagonist: a case report.
32185362 Persistence and Adherence during
the First Six Months of Tocilizumab Treatment
Among Rheumatoid Arthritis Patients in Routine
Clinical Practice in Greece. Results from the
Single Arm REMISSION II Study
32185340 Treatment of systemic sclerosis
associated fibrotic manifestations: Current
options and future directions.
32185277 Study of the natural course and
specific immunity after herpes zoster in patients
with rheumatoid arthritis receiving biologic
32183689 European Headache Federation
recommendations for neurologists managing
giant cell arteritis.
31249756 Early Initiation of Tocilizumab in
Clinically Isolated Aortitis.
31246724 Recurrent Stroke in Giant Cell
Arteritis Despite Immunotherapy.
31246342 LNRRIL6, a novel long non-coding
RNA, protects colorectal cancer cells by
activating the IL-6-STAT3 pathway.
31244353 Successful treatment with
tocilizumab for massive ascites due to
secondary amyloidosis complicating
rheumatoid arthritis: a case report.
31243259 Tocilizumab and rituximab have
similar effectiveness and are both superior to a
second tumour necrosis factor inhibitor in
rheumatoid arthritis patients who discontinued
a first TNF inhibitor.
31230059 Tocilizumab in refractory juvenile
idiopathic arthritis with associated uveitis: a
31223480 Effects of interleukin-6 receptor
blockade on allergen-induced airway responses
in mild asthmatics.
31219357 Tocilizumab for the treatment of
chimeric antigen receptor T cell-induced
cytokine release syndrome.
31213436 Remission maintenance after
tocilizumab dose-tapering and interruption in
patients with giant cell arteritis: an open-label,
18-month, prospective, pilot study.
31209481 Drug retention of biological DMARD
in rheumatoid arthritis patients: the role of
baseline characteristics and disease evolution.
31204508 Comparison of adverse events of
biologicals for treatment of juvenile idiopathic
arthritis: a systematic review.
31201793 Multiplexed monitoring of
therapeutic antibodies for inflammatory
diseases using Fab-selective proteolysis
nSMOL coupled with LC-MS.
31201070 Favorable Outcomes With Early
Interleukin 6 Receptor Blockade in Severe
Acute Necrotizing Encephalopathy of
31196844 Initiating tocilizumab, with or without
methotrexate, compared with starting
methotrexate with prednisone within step-up
treatment strategies in early rheumatoid
arthritis: an indirect comparison of effectiveness
and safety of the U-Act-Early and CAMERA-II
31187094 Tocilizumab in sarcoidosis patients
failing steroid sparing therapies and anti-TNF
31174825 Outcomes of patients with systemic
sclerosis treated with tocilizumab: Case series
and review of the literature.
31174819 Central nervous system involvement
in rheumatoid arthritis patients and the potential
implications of using biological agents.
31172726 The First Case Series of
Cryopyrin-Associated Periodic Syndrome in
31165299 The use of leukocytes' secretome to
individually target biological therapy in
autoimmune arthritis: a case report.
31159524 [Efficacy and safety of tocilizumab in
patients with Takayasu arteritis].
3970226 Tocilizumab in Children With ACP
3967691 IL-6 Regulation of Substrate
Metabolism and Influence of Obesity
3933904 Sirolimus in Previously Treated
Idiopathic Multicentric Castleman Disease
3923738 A Study to Evaluate the
Pharmacokinetics, Pharmacodynamics, and
Safety of Tocilizumab (TCZ) Administered to
Participants With Giant Cell Arteritis (GCA).
3895879 Use of Tocilizumab Drug Levels to
Optimize Treatment in RA
3892785 MEthotrexate Versus TOcilizumab for
Treatment of GIant Cell Arteritis: a Multicenter,
Randomized, Controlled Trial
3867617 Cell Therapy for Immunomodulation in
3863015 IL-6 Inhibition for Modulating
Inflammation After Cardiac Arrest
3859388 Longitudinal Changes in
Donor-Derived Cell-Free DNA With Tocilizumab
Treatment for Chronic Antibody-Mediated
3787290 Mild-Intensity Whole Body
Hyperthermia (WBH) for Major Depressive
3781310 Therapeutic Drug Monitoring of
Tocilizumab in Rheumatoid Arthritis
3745586 Giant Cell Arteritis Treatment With
Ultra-short Glucocorticoids and Tocilizumab
3726749 Tocilizumab Plus a Short Prednisone
Taper for GCA
3711448 Ustekinumab for the Treatment of
Relapse of Refractory Giant Cell Arteritis
3699631 PROACTIVE: Prevention of Acute and
Chronic GVHD Using TocIlizumab in
Combination With Standard GVHD Prophylaxis
After allogEneic Transplantation
3644667 Tocilizumab in Cardiac
3632187 Abatacept in earLy Onset Polymyalgia
Rheumatica: Study ALORS
3606876 Comparative Study to Evaluate the
Pharmacokinetics of BAT1806 vs Actemra® in
3588936 Nivolumab and Tocilizumab for
Relapsed Hematological Malignancy
3554161 Tocilizumab for the Treatment of
Refractory Behcet's Uveitis
⇧ Embed Print